Stoke Therapeutics Inc
STOK - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.7B
Close$
$-2.95
110.7% downside
Current Fair Value
110.7% downsideOvervalued by 110.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.70 Billion |
|---|---|
| Enterprise Value | $1.60 Billion |
| Earnings per Share | $-0.12 |
| Beta | 1.26 |
| Outstanding Shares | 68,362,880 |
Return
| Return on Equity | -70.38% |
|---|---|
| Return on Assets | -61.73% |
| Return on Invested Capital | -72.13% |
Valuation & Multiples
| P/E Ratio | -6.94 |
|---|---|
| PEG | -7.54 |
| Price to Sales | - |
| Price to Book Ratio | 5.49 |
| Enterprise Value to Revenue | 56.63 |
| Enterprise Value to EBIT | -6.29 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$-0.93
Consensus analyst estimateRevenue Estimate
$8.21 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 15, 2027
EPS Estimate
$-1.10
Consensus analyst estimateRevenue Estimate
$8.76 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 137.78% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.15%▼ 119.50% |
|---|---|
| Total Invested | $36.88M▼ 98.53% |
| Investors Holding | 32▼ 171.00% |
About Stoke Therapeutics Inc
CEO: Edward Kaye
